Noninvasive screening for unruptured intracranial aneurysms in patients with 2 first-degree relatives with SAH or intracranial aneurysms might be rea- sonable (Class IIb; Level of Evidence C).110 5. Noninvasive screening may be considered for unrup- tured intracranial aneurysms in patients with auto- somal-dominant polycystic kidney disease and 1 relatives with autosomal-dominant polycystic kidney disease and SAH or 1 relatives with autosomal- dominant polycystic kidney disease and intracranial aneurysm (Class IIb; Level of Evidence C). 6. Noninvasive screening for unruptured intracranial aneurysms in patients with cervical fibromuscu- lar dysplasia may be considered (Class IIb; Level of Evidence C). 7. Pharmacogenetic dosing of vitamin K antagonists may be considered when therapy is initiated (Class IIb; Level of Evidence C). 8. Noninvasive screening for unruptured intracranial aneurysms in patients with no more than 1 relative with SAH or intracranial aneurysms is not recom- mended (Class III; Level of Evidence C). 9. Screening for intracranial aneurysms in every car- rier of autosomal-dominant polycystic kidney disease or Ehlers-Danlos type IV mutations is not recom- mended (Class III; Level of Evidence C). 10. Genetic screening of the general population for the prevention of a first stroke is not recommended (Class III; Level of Evidence C). 11. Genetic screening to determine risk for myopathy is not recommended when initiation of statin therapy is being considered (Class III; Level of Evidence C). Well-Documented and Modifiable Risk Factors Physical Inactivity Physical inactivity is associated with numerous adverse health effects, including an increased risk of total mortality, cardio- vascular morbidity and mortality, and stroke. 